PeerView Oncology CME/CNE/CPE Audio Podcast

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.

In this activity, an expert in CRC management discusses contrasting approaches to treating elderly individuals presenting with advanced disease. Two case scenarios will illustrate how therapeutic decision-making may be influenced by patient health and performance status or a patients? willingness to pursue aggressive treatment. In addition, the clinical consequences of specific comorbidities or tumor-related factors will also be explored.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.

In this activity, an expert in iron overload discusses the differences between hereditary and transfusional hemochromatosis, and evaluates the role of iron chelation in the management of the latter, including both single-agent and combination approaches. New data on the ability of chelators to reduce cardiac iron burden in patients with transfusional iron overload are also discussed.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.

In this activity, experts in breast cancer discuss current evidence on the risk of cardiotoxicity associated with various breast cancer therapies and provide practical recommendations for preventing, monitoring and managing cardiovascular adverse effects in patients undergoing treatment for breast cancer.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.

In this activity, experts on breast cancer provide a concise summary of the latest and most clinically relevant data on endocrine therapies for breast cancer, and discuss how to integrate this information into everyday patient care.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.

In this program, an expert on kidney cancer provides a concise summary of the key aspects of the biology of renal cell carcinoma (RCC), characteristics of the targeted therapies, and strategies to effectively manage the adverse effects related to these agents.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.

Experts in MDS and AML discuss the clinical importance of new findings in these settings, specifically the following topics: an evaluation of modified induction/consolidation chemotherapy in AML, an update on epigenetic treatment and the potential of epigenetic combinations to augment activity in MDS and AML, and the relevance of newer prognostic models to a well-rounded clinical approach. Faculty will also discuss new data on the mechanisms of epigenetic agents, and whether these data possess prognostic or predictive implications.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.

In this program, an expert on brain tumors discusses the current perspectives and latest advances in the treatment of glioblastoma multiforme (GBM). Evidence-based guidelines for newly diagnosed as well as recurrent GBM are reviewed and analyzed, and recommendations for how to apply them in everyday practice are provided. Additionally, up-to-date data on novel therapies are evaluated, and ongoing clinical trials assessing some of the more promising emerging therapies are highlighted. These topics are discussed in the context of results from a survey of United States–based oncologists and neurosurgeons that was conducted to assess their knowledge of and approaches to treatment of GBM.

Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.